Globus Medical Inc. Insider Trading

GMED

Last 12 months

Insiders sold $17.5M and bought nothing on the open market.

39% of the selling was scheduled in advance under 10b5-1 plans. Director James R Tobin sold $2.24M on Sep 15, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Aug 2020.

Net open-market

−$17.5M

0 buys · 13 sales

Under a 10b5-1 plan

39%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Aug 2020

Aug 24, 2020

Get an email when GMED's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 15	James R Tobin Director	SoldNo plan	30,000	$74.58	$2.24M	100%	Form 4
Aug 18	Stephen T Zarrilli Director	SoldNo plan	25,000	$87.04	$2.18M	100%	Form 4
Jun 5	David D Davidar Director	SoldNo plan	25,000	$80.76	$2.02M	3.6%	Form 4
Feb 25	Kelly Huller EVP, GC, Corporate Secretary	Sold10b5-1 plan	20,000	$94.50	$1.89M	100%	Form 4
Feb 12	Kelly Huller EVP, GC, Corporate Secretary	Sold10b5-1 plan	10,000	$87.67	877K	100%	Form 4
Jan 8	Kyle Kline Senior Vice President, CFO	Sold10b5-1 plan	3,594	$101.10	363K	100%	Form 4
Jan 8	Leslie V Norwalk Director	Sold10b5-1 plan	2,000	$101.10	202K	16%	Form 4
Dec 12, 2025	Leslie V Norwalk Director	Sold10b5-1 plan	4,000	$88.85	355K	24%	Form 4
Dec 1, 2025	Kyle Kline Senior Vice President, CFO	Sold10b5-1 plan	18,542	$90.00	$1.67M	100%	Form 4
Nov 25, 2025	Kelly Huller SVP, GC, Corporate Secretary	Sold10b5-1 plan	7,500	$90.00	675K	100%	Form 4
Nov 12, 2025	David D Davidar Director	SoldNo plan	25,000	$86.00	$2.15M	3.5%	Form 4
Nov 11, 2025	Stephen T Zarrilli Director	SoldNo plan	25,000	$84.29	$2.11M	100%	Form 4
Nov 7, 2025 – Nov 10, 2025	Ann D Rhoads Director	Sold10b5-1 plan 2 parts	10,000	$81.80 average	818K	39%	Form 4
Sep 15, 2025	Ann D Rhoads Director	Sold10b5-1 plan	10,000	$58.46	585K	28%	Form 4
Feb 28, 2025	Ann D Rhoads Director	Sold10b5-1 plan	7,500	$78.68	590K	17%	Form 4
Jan 10, 2025	Keith W Pfeil COO, CFO	Sold10b5-1 plan 2 parts	14,167	$88.29 average	$1.25M	100%	Form 4
Dec 2, 2024	Kelly Huller SVP, GC, Corporate Secretary	Sold10b5-1 plan	2,500	$87.00	218K	100%	Form 4
Nov 21, 2024 – Nov 22, 2024	David D Davidar Director	Sold10b5-1 plan 4 parts	40,000	$85.00 average	$3.4M	4.5%	Form 4
Nov 21, 2024 – Nov 22, 2024	Dan Lemaitre Director	SoldNo plan 2 parts	14,375	$85.00 average	$1.22M	100%	Form 4
Nov 21, 2024	Daniel T Scavilla President, CEO	Sold10b5-1 plan	130,000	$85.00	$11.1M	100%	Form 4
Nov 6, 2024	Kelly Huller SVP, GC, Corporate Secretary	Sold10b5-1 plan 2 parts	5,000	$81.01 average	405K	100%	Form 4
Nov 6, 2024	Daniel T Scavilla President, CEO	Sold10b5-1 plan	60,000	$80.02	$4.8M	100%	Form 4

Sep 15No plan
James R Tobin
Director · sold 30,000 at $74.58
$2.24M
100% of stake
Aug 18No plan
Stephen T Zarrilli
Director · sold 25,000 at $87.04
$2.18M
100% of stake
Jun 5No plan
David D Davidar
Director · sold 25,000 at $80.76
$2.02M
3.6% of stake
Feb 2510b5-1 plan
Kelly Huller
EVP, GC, Corporate Secretary · sold 20,000 at $94.50
$1.89M
100% of stake
Feb 1210b5-1 plan
Kelly Huller
EVP, GC, Corporate Secretary · sold 10,000 at $87.67
877K
100% of stake
Jan 810b5-1 plan
Kyle Kline
Senior Vice President, CFO · sold 3,594 at $101.10
363K
100% of stake
Jan 810b5-1 plan
Leslie V Norwalk
Director · sold 2,000 at $101.10
202K
16% of stake
Dec 12, 202510b5-1 plan
Leslie V Norwalk
Director · sold 4,000 at $88.85
355K
24% of stake
Dec 1, 202510b5-1 plan
Kyle Kline
Senior Vice President, CFO · sold 18,542 at $90.00
$1.67M
100% of stake
Nov 25, 202510b5-1 plan
Kelly Huller
SVP, GC, Corporate Secretary · sold 7,500 at $90.00
675K
100% of stake
Nov 12, 2025No plan
David D Davidar
Director · sold 25,000 at $86.00
$2.15M
3.5% of stake
Nov 11, 2025No plan
Stephen T Zarrilli
Director · sold 25,000 at $84.29
$2.11M
100% of stake
Nov 7, 2025 – Nov 10, 202510b5-1 plan
Ann D Rhoads
Director · sold 10,000 at avg $81.80
818K
39% of stake
Sep 15, 202510b5-1 plan
Ann D Rhoads
Director · sold 10,000 at $58.46
585K
28% of stake
Feb 28, 202510b5-1 plan
Ann D Rhoads
Director · sold 7,500 at $78.68
590K
17% of stake
Jan 10, 202510b5-1 plan
Keith W Pfeil
COO, CFO · sold 14,167 at avg $88.29
$1.25M
100% of stake
Dec 2, 202410b5-1 plan
Kelly Huller
SVP, GC, Corporate Secretary · sold 2,500 at $87.00
218K
100% of stake
Nov 21, 2024 – Nov 22, 202410b5-1 plan
David D Davidar
Director · sold 40,000 at avg $85.00
$3.4M
4.5% of stake
Nov 21, 2024 – Nov 22, 2024No plan
Dan Lemaitre
Director · sold 14,375 at avg $85.00
$1.22M
100% of stake
Nov 21, 202410b5-1 plan
Daniel T Scavilla
President, CEO · sold 130,000 at $85.00
$11.1M
100% of stake
Nov 6, 202410b5-1 plan
Kelly Huller
SVP, GC, Corporate Secretary · sold 5,000 at avg $81.01
405K
100% of stake
Nov 6, 202410b5-1 plan
Daniel T Scavilla
President, CEO · sold 60,000 at $80.02
$4.8M
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch GMED, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with GMED

CompareIntrinsic value

MMEDMiniMed Group, Inc.

$19.29+2.33%25

PODDInsulet Corporation

$165.02+6.56%75

WSTWest Pharmaceutical Services, Inc.

$408.78+0.44%46

ICUIIcu Medical Inc.

$172.62+6.67%46

TFXTeleflex Incorporated

$149.87+7.09%16

IARTIntegra LifeSciences Holdings Corporation

$14.82+8.73%28

MMSIMerit Medical Systems, Inc.

$90.63+7.69%61

PENPenumbra Inc.

$322.45+0.76%72

Held by ETFs

GMED is in 139 US ETFs. The largest of them, with GMED's weight in each:

Spot a number that looks wrong? Check it in GMED's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GMED

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.